Hjem › Diffust stort B-celle lymfom
Diffust stort B-celle lymfom kliniske forsøg rekrutterer i USA
101 studier for Diffust stort B-celle lymfom rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- New York City, NY21 studier
- Baldwin Park, CA19 studier
- Chicago, IL18 studier
- Los Angeles, CA17 studier
- Houston, TX17 studier
- Boston, MA16 studier
- Milwaukee, WI16 studier
- Portland, OR15 studier
- Nashville, TN15 studier
- Philadelphia, PA15 studier
- Durham, NC14 studier
- Dallas, TX13 studier
- Seattle, WA12 studier
- Salt Lake City, UT12 studier
- Washington, DC12 studier
- Denver, CO11 studier
- Cincinnati, OH11 studier
- Cleveland, OH11 studier
- Rochester, MN10 studier
- Atlanta, GA10 studier
- Richmond, VA10 studier
- Columbus, OH9 studier
- Edison, NJ9 studier
- Omaha, NE9 studier
- Cedar Rapids, IA9 studier
- San Antonio, TX8 studier
- Sacramento, CA8 studier
- Greenburgh, NY8 studier
- Jacksonville, FL8 studier
- San Francisco, CA8 studier
- Louisville, KY8 studier
- St. Louis, MO8 studier
- New Haven, CT8 studier
- Grand Rapids, MI8 studier
- Charlottesville, VA7 studier
- Miami, FL7 studier
- Kansas City, MO7 studier
- Indianapolis, IN7 studier
- Aurora, CO7 studier
- Pittsburgh, PA6 studier
Efter delstat
- Alabama4 studier
- Arizona13 studier
- Arkansas4 studier
- Californien42 studier
- Colorado19 studier
- Connecticut8 studier
- District of Columbia4 studier
- Florida23 studier
- Georgia15 studier
- Idaho4 studier
- Illinois22 studier
- Indiana9 studier
- Iowa11 studier
- Kansas7 studier
- Kentucky11 studier
- Louisiana6 studier
- Maryland13 studier
- Massachusetts16 studier
- Michigan15 studier
- Minnesota16 studier
- Missouri8 studier
- Montana4 studier
- Nebraska9 studier
- Nevada3 studier
- New Jersey13 studier
- New Mexico3 studier
- New York31 studier
- North Carolina20 studier
- North Dakota4 studier
- Ohio23 studier
- Oklahoma5 studier
- Oregon15 studier
- Pennsylvania19 studier
- South Carolina4 studier
- South Dakota3 studier
- Tennessee19 studier
- Texas29 studier
- Utah14 studier
- Virginia17 studier
- Washington17 studier
- Wisconsin19 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06500273Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06863402Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06834373Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07763210Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruttererObservationsstudie
Alder 0 til 38 · Alle køn · Opdateret 1. okt. 2026 · NCT06131801Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06649812Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT06977711Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
RekruttererFase 2
Alder 65 til 99 · Alle køn · Opdateret 29. sep. 2026 · NCT05952024A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05006716Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT03418038Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RekruttererFase 1/2
Alder 18 til 120 · Alle køn · Opdateret 28. sep. 2026 · NCT03223610A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06717347A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06091865A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07519772A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05139017A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06890884Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT06784167A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RekruttererFase 1/2
6 Months – 25 Years · Alle køn · Opdateret 17. sep. 2026 · NCT06395103Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT05757219Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT04002947A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06806033Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. sep. 2026 · NCT05272384Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.